Clinical trials: Breast Cancer (Early Breast Cancer)
Breast Cancer
Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer
RATIONALE: The combination of anti-angiogenic targeted therapy with neoadjuvant chemotherapy has been shown to further improve the pathologic response rate for HER2-negative breast cancer patients.
- Trial name
- APP (NCT03982485)
- Testing
- Apatinib, Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 196 people
- Sponsor
- RenJi Hospital
Breast Cancer
Circulating MicroRNA as Biomarker of Cardiotoxicity in Breast Cancer
In the proposed project the investigators will asses whether changes in expression of selected circulating microRNAs in serum could comprise a sensitive and specific biomarker of cardiotoxicity in cancer patients treated with…
- Trial name
- NCT02065908
- Where
- 3 sites in Poland
- Volunteers
- 128 people
- Sponsor
- West Pomeranian Cancer Center
Breast Cancer
Postoperative Identification of Tumor Cells At the Lumpectomy Site of Patients with Early Breast Cancer
For early breast cancer, local surgery followed by breast radiation is a standard local treatment. It has been found that the original primary tumor site, the lumpectomy site, is the commonest location of local relapse.
- Trial name
- NCT04339517
- Testing
- Aspiration of seroma fluid
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Arthralgia
Effect of Acupuncture vs Chinese Medicine vs Combined Therapy on Aromatase Inhibitor-related Arthralgia Among Women With Early-Stage Breast Cancer
Aromatase inhibitors have been used to treat hormone receptor positive breast cancer women in menopause, but side effects, such as joint pain, would affect their qualities of life.
- Trial name
- NCT05264649
- Testing
- acupuncture, Guizhi-Shaoyao-Zhimu decoction
- Where
- Taiwan
- Volunteers
- 72 people
- Sponsor
- Show Chwan Memorial Hospital
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Adjuvant Treatment in Premenopausal Breast Cancer
Multicentric retroprospective observational study to collect outcome in premenopausal breast cancer patients who undergone the 21-multigene assay Oncotype DX from 1st January 2013 to 31st December 2022 and adjuvant treatment.
- Trial name
- PERSEVEREX (NCT06807749)
- Where
- 2 sites in Italy
- Volunteers
- 800 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative…
- Trial name
- ELEGANT (NCT06492616)
- Testing
- Elacestrant, Anastrozole, Letrozole
- Where
- 567 sites in United States, Argentina and 26 more
- Volunteers
- 4,220 people
- Sponsor
- Stemline Therapeutics, Inc.
HER2-negative Breast Cancer
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who…
- Trial name
- FB-12 (NCT03412643)
- Testing
- Doxorubicin, Cyclophosphamide, Weekly Paclitaxel
- Where
- 43 sites in United States
- Volunteers
- 64 people
- Sponsor
- NSABP Foundation Inc
Early-stage Breast Cancer
Sentinel Lymph Node Identification in Patients With Breast Cancer Using SPECT/CT
Role of SPECT/CT in detection of sentinel lymph node in patients with breast cancer that is in early stage with small mass with no nodal or distant metastasis using radioactive material nannocolloid that can change surgical…
- Trial name
- NCT03468374
- Testing
- lymphoscintigraphy, Single Photon Emission Tomography
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Assiut University
Breast Cancer
SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.
The study is being conducted to assess effect of SHR6390 combined with anastrozole on proliferation of HR-positive HER2-negative breast cancer tumor cells before surgery.
- Trial name
- NCT04836520
- Testing
- SHR6390+anatrozole
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer, Ovarian Cancer
Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation
Despite relevant clinical and/or familial presentations suggesting a hereditary predisposition (early-onset, multiple primary tumors, familial aggregation), targeted genomic analysis based on the phenotype are often non…
- Conditions
- Breast Cancer, Ovarian Cancer, Colorectal Cancer, Pediatric Cancers
- Trial name
- PANEL (NCT02664389)
- Testing
- Genetic analysis
- Where
- France
- Volunteers
- 289 people
- Sponsor
- University Hospital, Rouen
Breast Neoplasms
Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy
The purpose of this study is to follow safety and quality of life outcomes on patients switching from tamoxifen therapy to aromatase inhibitor therapy.
- Trial name
- TAMARA (NCT00784888)
- Testing
- Aromatase inhibitors
- Where
- 16 sites in Turkey (Türkiye)
- Volunteers
- 344 people
- Sponsor
- Pfizer
Breast Cancer
Exercise Regimen Designed to Improve Functional Mobility, Body Composition, and Strength After Breast Conservation Therapy for Women With Early Stage Breast Cancer
The purpose of this research study is to find out if a monitored group exercise program can increase strength, muscle mass and ability to move in women after treatment for early stage breast cancer.
- Trial name
- EXERT-BC (NCT04449809)
- Testing
- Exercise program
- Where
- United States
- Sponsor
- Duke University
Breast Cancer
IMproving PAtient UndeRstanding of GEP TEst Results: Phase 4
The primary aim of the study is to determine if provision of a patient information film about Oncotype DX improves patients' knowledge and understanding about Gene Expression Profiling (GEP) test and risk of recurrence results in…
- Trial name
- IMPARTER (NCT06703567)
- Testing
- Standard Policy, Standard Policy + GEP Information Film
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- European Institute of Oncology
Breast Cancer, Lung Cancer
Impact of Geriatrician Interventions on Chemotherapy Delivery in Vulnerable Elderly Oncology Patients
This is a randomized parallel group trial designed to evaluate the impact of implementing geriatrician-prescribed interventions based on the comprehensive geriatric assessment (CGA), on the ability to deliver adequate…
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- GIVE (NCT02785887)
- Testing
- Geriatrician review
- Where
- 3 sites in Italy
- Volunteers
- 233 people
- Sponsor
- Azienda USL 4 Prato
HER2-positive Breast Cancer
PIK3CA in HER2+ BC and pCR Trial
The goal of the study is to evaluate the impact of somatic PI3KCA mutations on pCR in HER2-positive early breast cancer in real life. The main question it aims to answer iS.
- Trial name
- NCT05750693
- Testing
- PIK3CA analysis
- Where
- Italy
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer
Promoting Early Detection of Breast Cancer in Rural Rwanda: Impact of Community Health Worker and Nurse Training
This project proposes a pilot intervention in Burera District to train rural Rwandan community health workers (CHWs) in breast awareness, and to train primary care nurses at rural health centers in the assessment and management…
- Trial name
- BCED (NCT03919682)
- Testing
- Experimental: Training, Phase 1, Experimental: Training, Phase 2
- Volunteers
- 1,203 people
- Sponsor
- Brigham and Women's Hospital
Breast Cancer
A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
This Phase IIIb, open-label, multinational, multicenter study will evaluate the participant's satisfaction and safety with subcutaneously administered trastuzumab in participants with HER2-positive early breast cancer.
- Trial name
- NCT01964391
- Testing
- Trastuzumab, Doxorubicin, Cyclophosphamide
- Where
- 23 sites in Algeria, Morocco and 3 more
- Volunteers
- 174 people
- Sponsor
- Hoffmann-La Roche
Triple Negative Breast Cancer
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
This is single arm study of a window of opportunity in which participants with previously untreated triple negative breast cancers (TNBC) who are candidates for potentially curative surgery will receive lenvatinib 12 mg daily for…
- Trial name
- NCT04427293
- Testing
- Lenvatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Illinois Chicago
Breast Cancer
Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00820872
- Testing
- trastuzumab, carboplatin, docetaxel
- Where
- 136 sites in United States
- Volunteers
- 30 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Neoplasm Female, Quality of Life
PRO Survivorship Concerns ITA
Breast cancer survivors typically experience fatigue, pain, insomnia, depression, anxiety, difficulty in concentrating, memory impairment, body image problems, vaginal dryness, interest in sex decreasing, hot flashes, gain…
- Conditions
- Breast Neoplasm Female, Quality of Life, Psychological Distress
- Trial name
- PRO (NCT06080607)
- Testing
- Patient Reported Outcome (PRO)
- Where
- 2 sites in Italy
- Volunteers
- 280 people
- Sponsor
- Regina Elena Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.